NCT04064905View on ClinicalTrials.gov

Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

July 30, 2019

Primary Completion Date

March 22, 2021

Study Completion Date

March 22, 2021

Conditions

Zika Virus

Interventions

BIOLOGICAL

mRNA-1893

Zika vaccine

OTHER

Placebo

0.9% sodium chloride

Trial Locations (4)

68134

Meridan Clinical Research, Omaha

76135

Benchmark Research, Fort Worth

78705

Benchmark Research, Austin

00716

Ponce School of Medicine - CAIMED Center, Ponce

All Listed Sponsors

collaborator

Biomedical Advanced Research and Development Authority

FED

lead

ModernaTX, Inc.

INDUSTRY

NCT04064905 - Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults | Biotech Hunter | Biotech Hunter